A randomised, open-label, multicentre, Phase III trial of in vivo purging with anti-CD38 (Daratumumab) to enhance myeloma autografting (IPANEMA)
- Hodgkinson, Andrea (Co-Investigator)
- Siddique, Shamyla (Co-Investigator)
- Gates, Simon (Co-Investigator)
- Craddock, Charles (Principal Investigator)